Key result
CRT-D is linked to ~68% higher late surgical complication risk vs. CRT-P, driven by infection.
Why the study?
The impact of adding a defibrillator to cardiac resynchronisation therapy on acute and late device-related complications in primary prevention patients has not been well studied.
Does cardiac resynchronisation therapy with a defibrillator (CRT-D) increase device-related complications compared to CRT-pacemaker (CRT-P) in patients with dilated cardiomyopathy?
Cohort (n=3,008)
Yes
Does cardiac resynchronisation therapy with a defibrillator (CRT-D) increase device-related complications compared to CRT-pacemaker (CRT-P) in patients with dilated cardiomyopathy?
Adding a defibrillator to cardiac resynchronization therapy (CRT-D) significantly increases the risk of late device-related complications, particularly infections, compared to CRT-pacemaker (CRT-P).
May warrant caution selecting CRT-D over CRT-P; leaves open optimal device choice without randomized confirmation.
OBJECTIVE: In patients indicated for cardiac resynchronisation therapy (CRT), the choice between a CRT-pacemaker (CRT-P) versus defibrillator (CRT-D) remains controversial and indications in this setting have not been well delineated. Apart from inappropriate therapies, which are inherent to the presence of a defibrillator, whether adding defibrillator to CRT in the primary prevention setting impacts risk of other acute and late device-related complications has not been well studied and may bear relevance for device selection. METHODS: Observational multicentre European cohort study of 3008 consecutive patients with ischaemic or non-ischaemic dilated cardiomyopathy and no history of sustained ventricular arrhythmias, undergoing CRT implantation with (CRT-D, n=1785) or without (CRT-P, n=1223) defibrillator. Using propensity score and competing risk analyses, we assessed the risk of significant device-related complications requiring surgical reintervention. Inappropriate shocks were not considered except those due to lead malfunction requiring lead revision. RESULTS: Acute complications occurred in 148 patients (4.9%), without significant difference between groups, even after considering potential confounders (OR=1.20, 95% CI 0.72 to 2.00, p=0.47). During a mean follow-up of 41.4±29 months, late complications occurred in 475 patients, giving an annual incidence rate of 26 (95% CI 9 to 43) and 15 (95% CI 6 to 24) per 1000 patient-years in CRT-D and CRT-P patients, respectively. CRT-D was independently associated with increased occurrence of late complications (HR=1.68, 95% CI 1.27 to 2.23, p=0.001). In particular, when compared with CRT-P, CRT-D was associated with an increased risk of device-related infection (HR 2.10, 95% CI 1.18 to 3.45, p=0.004). Acute complications did not predict overall late complications, but predicted device-related infection (HR 2.85, 95% CI 1.71 to 4.56, p<0.001). CONCLUSIONS: Compared with CRT-P, CRT-D is associated with a similar risk of periprocedural complications but increased risk of long-term complications, mainly infection. This needs to be considered in the decision of implanting CRT with or without a defibrillator.
No takes yet. Share an insight, caveat, or question.
Barra et al. (2018) conducted a cohort in Ischaemic or non-ischaemic dilated cardiomyopathy without history of sustained ventricular arrhythmias (n=3,008). Cardiac resynchronization therapy with defibrillator (CRT-D) vs. Cardiac resynchronization therapy with pacemaker (CRT-P) was evaluated on Late device-related complications requiring surgical re-intervention (HR 1.68, 95% CI 1.27-2.23, p=0.001). Compared to CRT-P, CRT-D was associated with a significantly increased risk of late device-related complications requiring surgical re-intervention (HR 1.68, 95% CI 1.27-2.23, p=0.001), mainly driven by infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: